{"prompt": "['12', 'MC1488 WEE1', 'MCCC', 'previously observed in studies of shorter duration. Observations in rat and dog toxicology', 'studies are generally monitorable and with evidence of reversibility within a 4-week', 'recovery period were demonstrated to be reversible following a 2 week recovery period.', 'These studies support continued clinical trials in subjects with advanced stage cancer.', '1.4', 'Clinical Experience with AZD1775', 'The following overview of the clinical experience with AZD1775 is based on the', 'knowledge available at the time this protocol was written and is based on Edition 12 of', \"the Investigator's Brochure, Edition 12, dated 18 February 2015, with a data cut-off date\", 'of 11 November 2014. For more detailed and up-to-date information, please consult the', \"current Investigator's Brochure.\", 'As of 11 November 2014, a total of 372 patients have been exposed to AZD1775 in', 'AstraZeneca-sponsored or Merck-sponsored clinical studies, which include 1 completed', 'study (Study PN001), 2 studies that were terminated early (Studies PN005 and PN008)', 'and 3 ongoing studies (Studies PN004, D6011C00001, and D6011C00002).', 'PN001: a first-time-in-patients (FTIP), Phase I, dose-escalation study evaluating', 'AZD1775 both as monotherapy and combination therapy with gemcitabine, cisplatin,', 'or carboplatin in adult patients with advanced solid tumours. This study has been', 'completed except for Part 3.', 'PN005: a Phase I, dose-escalation study evaluating AZD1775 as monotherapy (Part', '1), combination therapy with 5-FU (Part 2), and combination therapy with 5-FU plus', 'cisplatin (Part : 3) in adult Japanese patients with advanced solid tumours. This study', 'was terminated early due to portfolio prioritization in oncology at Merk after 3', 'patients had been enrolled in Part 1 and 8 patients had been enrolled in Part 2. Part 3', 'was not initiated.', 'PN008: a Phase I/IIa, dose-escalation study evaluating AZD1775 in combination', 'with topotecan plus cisplatin in adult patients with cervical cancer was terminated', 'early due to portfolio prioritization in oncology at Merk after 7 patients had been', 'enrolled in the dose-escalation part of the study. The Phase IIa part was not initiated.', 'PN004: a Phase II study evaluating AZD1775 combined with carboplatin and', 'paclitaxel in patients with platinum-sensitive p53-mutant ovarian cancer. This study', 'is ongoing.', 'D6011C00001: a lead-in Phase II multicentre, randomised, double-blind study', 'comparing AZD1775 plus docetaxel with placebo plus docetaxel in previously', 'treated patients with non-small-cell lung cancer. This study is ongoing.', 'D6011C00002: a Phase II study of AZD1775 plus pemetrexed and carboplatin', 'followed by a randomised comparison of pemetrexed and carboplatin with or without', 'AZD1775 in patients with previously untreated stage IV non-squamous non-small', 'cell lung cancer. This study is ongoing.', 'In addition, 93 patients have also received AZD1775 as part of externally-sponsored', 'scientific research. These patients have received single doses per cycle as high as 1300', 'mg of AZD1775 as monotherapy, 325 mg of AZD1775 in a single-dose in combination']['13', 'MC1488 WEE1', 'MCCC', 'with chemotherapy, and 325 mg twice a day (BID) in a multiple-dose regimen in', 'combination with chemotherapy.', '1.41', 'Clinical Safety', 'Several clinical studies with AZD1775 alone and in combination with (mostly full dose)', 'cytotoxic chemotherapy have been conducted.', 'The MTD of AZD1775 monotherapy has not been established. Single doses of AZD1775', 'up to 1300 mg were well tolerated.', 'The MTDs of AZD1775 when administered with chemotherapy are presented in the table', 'below:', 'Maximum-tolerated doses of AZD1775 when administered in combination with chemotherapy', 'Chemotherapy', 'Dose Frequency', 'AZD1775 (mg)', 'Gemcitabine 1000 mg/m\u00b2 on Day 1 weekly for', 'Single-dose', '200', '3 consecutive weeks out of every 4 weeks', 'Cisplatin 75 mg/m2 on Day 1 every 21 days', 'Single-dose', '200', 'Carboplatin AUC 5 on Day 1 every 21 days', 'Single-dose', '325', 'Gemcitabine 1000 mg/m2 on Day 1 weekly for', 'Multi-dose', '175 QD x2 days', '3', 'consecutive weeks out of every 4 weeks', 'Cisplatin 75 mg/m2 on Day 1 every 21 days', 'Multi-dose', '200 BID X 2.5 days', 'Carboplatin AUC 5 on Day 1 every 21 days', 'Multi-dose', '225 BID X 2.5 days', 'BID = twice daily; QD = once daily', 'There were no DLTs observed for patients receiving monotherapy with AZD1775. For', 'combination treatments, DLT rates at all MTDs were less than 30% in Study PN001.', 'Oral administration of AZD1775 both as monotherapy and in combination with', 'gemcitabine, cisplatin, or carboplatin in patients with advanced solid tumours was', 'tolerable.', 'Based on the safety data from the 3 completed clinical studies, the most frequently', 'reported drug-related AEs were blood and lymphatic disorders (neutropenia,', 'thrombocytopenia, anaemia), gastrointestinal disorders (diarrhoea, vomiting, nausea), and', 'general disorders and administration site conditions (fatigue, pyrexia).', 'The most frequently reported SAEs occurred within the gastrointestinal, infections and', 'infestations, and blood and lymphatic disorders system organ classes. The SAEs reported', 'to be related to study medication in PN001 included nausea, vomiting, diarrhoea, gastric', 'ulcer, colitis, dehydration, pyrexia, hemiparesis, renal impairment, renal failure, urinary', 'tract infection, dyspnoea, recall phenomenon, palpitations, lung infiltration, agitation,', 'neutropenia, febrile neutropenia, anaemia, thrombocytopenia, leukopenia, increased', 'blood creatinine, and hyperbilirubinaemia. Events that led to death in that study included', 'malignant neoplasm progression, renal failure, respiratory failure, pneumonia, hypoxia,', 'and lung infiltration.', 'Cardiac disorders (tachycardia, palpitations, QTc prolongation) and gastrointestinal', 'haemorrhage were not observed frequently, but are considered to be important potential', 'risks.']\n\n###\n\n", "completion": "END"}